TARGETING more patients
Our pipeline
With a focus on novel cell therapies for cancer, Chimeric currently has three novel cell therapies in four clinical 1 trials. Each has advanced to human trials.
Our first asset, CHM CDH17, is in clinical trials for gastric and pancreatic cancers and colorectal cancers. Our second asset, CHM CLTX, is being applied the brain cancer, Gioblastoma. And finally, with our third platform, the CHM CORE NK platform, we're addressing blood cancer AML, as well as testing in patients with colorectal cancer.
BUILDING A CELL THERAPY PORTFOLIO
T cells & NK Cells
Cell therapy (also called cellular therapy, cell transplantation, or cytotherapy) is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T cells or NK cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy.
Due to the important and global unmet needs that cell therapy has the potential to address, the therapy has an orphan designation from the FDA in the USA. This designation can flow on to other markets, and requires fewer phases in clinical trails versus traditional pharmaceuticals. Cell therapies may also be registered in Phase 2, resulting in a faster path to market and earlier inflection points for investors.
